Reply letter to “response to article by Johnna Perdrizet et al.” by Gomez and colleagues
This communication seeks to address the questions and criticisms issued by Gomez and colleagues in their letter on our original study “Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil inf...
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
Taylor & Francis Group
2022-01-01
|
| Collection: | Human Vaccines & Immunotherapeutics |
| Accès en ligne: | http://dx.doi.org/10.1080/21645515.2021.1917237 |
| Résumé: | This communication seeks to address the questions and criticisms issued by Gomez and colleagues in their letter on our original study “Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants.” Gomez and colleagues are concerned that the assumptions used in our model may have unintended negative impacts for Brazil decision-making and we intend to clarify any potential misinterpretation of our assessment. |
|---|---|
| ISSN: | 2164-5515 2164-554X |